BCR—ABL35INS突变型慢性粒细胞白血病患者选用酪氨酸激酶抑制剂的文献分析(4)
[ 4 ] LEE T，MA W，ZHANG X，et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance：evidence from molecular dynamics simulations[J]. Mol Cancer Ther，2008，7(12)：3834-3841.[ 5 ] ZWAAN CM，RIZZARI C，MECHINAUD F，et al. Dasatinib in children and adolescents with relapsed or refractory leukemia：results of the CA180-018 phase Ⅰdose-escalation study of the innovative therapies for children with cancer consortium[J]. J Clin Oncol ......
您现在查看是摘要页，全文长 2667 字符。